Abstract
AbstractDiabetes mellitus is a disease of dysregulated blood glucose homeostasis. The current pandemic of diabetes is a significant driver of patient morbidity and mortality, as well as a major challenge to healthcare systems worldwide. The global increase in the incidence of diabetes has prompted researchers to focus on the different pathogenic processes responsible for type 1 and type 2 diabetes. Similarly, increased morbidity due to diabetic complications has accelerated research to uncover pathological changes causing these secondary complications. Albuminuria, or protein in the urine, is a well-recognised biomarker and risk factor for renal and cardiovascular disease. Albuminuria is a mediator of pathological abnormalities in diabetes-associated conditions such as nephropathy and atherosclerosis. Clinical screening and diagnosis of diabetic nephropathy is chiefly based on the presence of albuminuria. Given the ease in measuring albuminuria, the potential of using albuminuria as a biomarker of cardiovascular diseases is gaining widespread interest. To assess the benefits of albuminuria as a biomarker, it is important to understand the association between albuminuria and cardiovascular disease. This review examines our current understanding of the pathophysiological mechanisms involved in both forms of diabetes, with specific focus on the link between albuminuria and specific vascular complications of diabetes.
Funder
Medical Research Council
National Centre for the Replacement, Refinement and Reduction of Animals in Research
Invest Northern Ireland
Department for Education
Pathological Society of Great Britain and Ireland
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Cardiology and Cardiovascular Medicine,Pharmacology,General Medicine
Reference140 articles.
1. Organization WH. Diabetes [Internet]. [cited 2020 Jun 1]. https://www.who.int/news-room/fact-sheets/detail/diabetes
2. Diagnosis and Classification of Diabetes Mellitus. Diabetes Care [Internet]. 2014;37:S81 LP-S90. http://care.diabetesjournals.org/content/37/Supplement_1/S81.abstract
3. NICE guideline. Type 2 diabetes in adults : management. NICE Guide 28. NICE Guid [Internet]. 2019;NG28:1–57. https://www.nice.org.uk/guidance/ng28/resources/type-2-diabetes-in-adults-management-1837338615493
4. Mostafa SA, Coleman RL, Agbaje OF, Gray AM, Holman RR, Bethel MA. Modelling incremental benefits on complications rates when targeting lower HbA1c levels in people with type 2 diabetes and cardiovascular disease. Diabet Med . John Wiley & Sons, Ltd (10.1111). 2018;35:72–7.
5. Kweka B, Lyimo E, Kidola J, Filteau S, Friis H, Manjurano A, et al. Validity of HbA1c in diagnosing diabetes among people with sickle cell trait in Tanzania. Blood. 2019;134:4852.
Cited by
21 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献